The CC chemokine RANTES in breast carcinoma progression: regulation of expression and potential mechanisms of promalignant activity E Azenshtein, G Luboshits, S Shina, E Neumark, D Shahbazian, M Weil, ... Cancer research 62 (4), 1093-1102, 2002 | 424 | 2002 |
The chemokine CCL5 as a potential prognostic factor predicting disease progression in stage II breast cancer patients N Yaal-Hahoshen, S Shina, L Leider-Trejo, I Barnea, EL Shabtai, ... Clinical cancer research 12 (15), 4474-4480, 2006 | 158 | 2006 |
The expression of the chemokine receptor CXCR3 and its ligand, CXCL10, in human breast adenocarcinoma cell lines L Goldberg-Bittman, E Neumark, O Sagi-Assif, E Azenshtein, T Meshel, ... Immunology letters 92 (1-2), 171-178, 2004 | 102 | 2004 |
Concomitant expression of the chemokines RANTES and MCP-1 in human breast cancer: a basis for tumor-promoting interactions G Soria, N Yaal-Hahoshen, E Azenshtein, S Shina, L Leider-Trejo, L Ryvo, ... Cytokine 44 (1), 191-200, 2008 | 92 | 2008 |
The angiogenic factors CXCL8 and VEGF in breast cancer: regulation by an array of pro-malignancy factors E Azenshtein, T Meshel, S Shina, N Barak, I Keydar, A Ben-Baruch Cancer letters 217 (1), 73-86, 2005 | 63 | 2005 |
Melanoma antigens and related immunological markers J Pitcovski, E Shahar, E Aizenshtein, R Gorodetsky Critical reviews in oncology/hematology 115, 36-49, 2017 | 40 | 2017 |
The effect of haptens on protein‐carrier immunogenicity T Gefen, J Vaya, S Khatib, I Rapoport, M Lupo, E Barnea, A Admon, ... Immunology 144 (1), 116-126, 2015 | 34 | 2015 |
The impact of PEGylation on protein immunogenicity T Gefen, J Vaya, S Khatib, N Harkevich, F Artoul, ED Heller, J Pitcovski, ... International immunopharmacology 15 (2), 254-259, 2013 | 33 | 2013 |
Intra-tumoral metabolic zonation and resultant phenotypic diversification are dictated by blood vessel proximity S Kumar, H Sharife, T Kreisel, M Mogilevsky, L Bar-Lev, M Grunewald, ... Cell metabolism 30 (1), 201-211. e6, 2019 | 26 | 2019 |
Adsoption of two vaccine-related proteins to montmorillonite and organo-montmorillonite G Rytwo, A Mendelovits, D Eliyahu, J Pitcovski, E Aizenshtein Applied clay science 50 (4), 569-575, 2010 | 18 | 2010 |
Spatial-fluxomics provides a subcellular-compartmentalized view of reductive glutamine metabolism in cancer cells WD Lee, D Mukha, E Aizenshtein, T Shlomi Nature communications 10 (1), 1-14, 2019 | 17 | 2019 |
Immunological complex for enhancement of innate immune response in passive vaccination E Aizenshtein, Y Pinchasov, E Morag, G Leitner, Y Shpanir, D Reimond, ... Vaccine 31 (4), 626-631, 2013 | 15 | 2013 |
Overcoming the susceptibility gap between maternal antibody disappearance and auto-antibody production R Yosipovich, E Aizenshtein, R Shadmon, S Krispel, E Shuster, ... Vaccine 33 (3), 472-478, 2015 | 12 | 2015 |
Systemic succinate homeostasis and local succinate signaling affect blood pressure and modify risks for calcium oxalate lithogenesis A Khamaysi, S Anbtawee-Jomaa, M Fremder, H Eini-Rider, ... Journal of the American Society of Nephrology 30 (3), 381-392, 2019 | 8 | 2019 |
Practical aspects in the use of passive immunization as an alternative to attenuated viral vaccines E Aizenshtein, R Yosipovich, M Kvint, R Shadmon, S Krispel, E Shuster, ... Vaccine 34 (22), 2513-2518, 2016 | 8 | 2016 |
Targeted microbeads for attraction and induction of specific innate immune response in the tumor microenvironment E Shahar, R Gorodetsky, E Gaberman, E Aizenshtein, J Pitcovski Vaccine 28 (45), 7279-7287, 2010 | 7 | 2010 |
Fast and sensitive flow-injection mass spectrometry metabolomics by analyzing sample-specific ion distributions B Sarvin, S Lagziel, N Sarvin, D Mukha, P Kumar, E Aizenshtein, T Shlomi Nature communications 11 (1), 1-11, 2020 | 5 | 2020 |
Mannosamine–biotin as a novel masking agent for coating IgG for immune response silencing and augmentation of antibody–antigen interaction J Vaya, E Aizenshtein, S Khatib, T Gefen, M Fassler, R Musa, S Krispel, ... Vaccine 27 (49), 6869-6876, 2009 | 5 | 2009 |
Coated cross-species antibodies by mannosamine–biotin adduct confer protection against snake venom without eliciting humoral immune response T Gefen, J Pitcovski, J Vaya, S Khatib, S Krispel, ED Heller, E Gaberman, ... Vaccine 28 (51), 8197-8202, 2010 | 3 | 2010 |
Formation of multimeric antibodies for self-delivery of active monomers Y Dekel, Y Machluf, T Gefen, G Eidelshtein, A Kotlyar, Y Bram, E Shahar, ... Drug delivery 24 (1), 199-208, 2017 | 2 | 2017 |